Joanne Silberner
Joanne Silberner is a health policy correspondent for National Public Radio. She covers medicine, health reform, and changes in the health care marketplace.
Silberner has been with NPR since 1992. Prior to that she spent five years covering consumer health and medical research at U.S. News & World Report. In addition she has worked at Science News magazine, Science Digest, and has freelanced for various publications. She has been published in The Washington Post, Health, USA Today, American Health, Practical Horseman, Encyclopedia Britannica, and others.
She was a fellow for a year at the Harvard School of Public Health, and from 1997-1998, she had a Kaiser Family Foundation media fellowship. During that fellowship she chronicled the closing of a state mental hospital. Silberner also had a fellowship to study the survivors of the bombings of Hiroshima and Nagasaki.
Silberner has won awards for her work from the Society of Professional Journalists, the New York State Mental Health Association, the March of Dimes, Easter Seals, the American Heart Association, and others. Her work has also earned her a Unity Award and a Clarion Award.
A graduate of Johns Hopkins University, Silberner holds her B.A. in biology. She has a master's degree in journalism from Columbia University Graduate School of Journalism.
She currently resides in Washington, D.C.
-
Globally, boys and young men made up two-thirds of all deaths among young people in 2019. A recent report finds that many such deaths in this "neglected" age group are preventable. -
For decades, Western docs and nurses have parachuted into poor countries to perform surgeries. That's not working in this pandemic. But there's a new twist that holds promise. -
Health officials have been investigating an extremely rare side-effect of vaccination with the mRNA vaccines in young people: heart inflammation that's mostly mild and temporary. -
When a new drug is up for FDA approval, trials may be held not only in the U.S. but other countries too. A study looks at global availability after approval. Big Pharma disagrees with the findings.
-
COVID-19 has renewed interest in a key way humans perceive the world. A reporter who hasn't been able to tell the scent of a rose from a sweaty gym shoe for decades takes heart in the latest science. -
That's the perspective in new papers in Lancet Global Health that assess the nearly a quarter of a million studies on treatments for COVID-19. -
The spread of new strains raises new questions as two COVID-19 vaccines continue their rollout across the U.S. and another vaccine candidate preps for regulatory review. Here's what you need to know. -
It takes time after vaccination for immunity to the virus to build up, and no vaccine is 100% effective. Plus, scientists don't yet know if the vaccine stops viral spread. Here's what's known so far. -
States are starting to administer their first doses of two newly FDA-authorized COVID-19 vaccines. It marks a new phase in the pandemic, but what's that mean for you? -
When the pandemic hit, mental health professionals predicted lockdowns and social distancing would result in a wave of loneliness. But researchers who study loneliness say that hasn't happened.
